Vaishali Pharma Clarifies Preferential Issue Pricing in NSE-Directed Postal Ballot Corrigendum

Vaishali Pharma Ltd. ( (IN:VAISHALI) ) has provided an announcement.

Vaishali Pharma Ltd. has issued a corrigendum to its postal ballot notice following directions from the National Stock Exchange, providing additional details and amendments under SEBI’s capital and disclosure rules. The update clarifies the valuation basis and pricing for subscription shares to be allotted on a preferential basis, setting a floor price of Rs 9.46 per share and a final issue price of Rs 20 per share, which could influence shareholder dilution, capital structure, and market perception of the company’s equity valuation.

The corrigendum specifies that the issue price is derived from a registered valuer’s reports and volume-weighted average prices over 90 and 10 trading days preceding the relevant date. By formally aligning the preferential allotment pricing with regulatory requirements and disclosing the equity swap and valuation methodology, the company seeks to reinforce compliance, transparency, and investor confidence ahead of the ongoing remote e-voting on the proposed transaction.

More about Vaishali Pharma Ltd.

Vaishali Pharma Ltd. operates in the pharmaceutical sector, with its equity shares listed on the National Stock Exchange of India. The company engages in capital market transactions governed by SEBI’s Issue of Capital and Disclosure Requirements Regulations, indicating an active focus on equity-based funding and corporate restructuring activities within India’s regulated capital markets.

Average Trading Volume: 238,097

Technical Sentiment Signal: Sell

Current Market Cap: 747.1M INR

For an in-depth examination of VAISHALI stock, go to TipRanks’ Overview page.